MktsMarkets

Janux Therapeutics, Inc.
NASDAQ: JANXKey statistics
JANX News
Stories mentioning JANX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 26,813 | 31,548 | 34,629 | 34,664 | 25,055 | 20,806 | 18,614 | 14,898 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (34,213) | (42,401) | (35,251) | (45,118) | (34,897) | (29,022) | (35,842) | (13,822) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (24,361) | (31,946) | (24,313) | (33,858) | (23,508) | (20,216) | (28,059) | (5,959) |
| Earnings Per Share (Basic) | (0.39) | (0.52) | (0.39) | (0.55) | (0.38) | (0.38) | (0.51) | (0.11) |
| Earnings Per Share (Diluted) | (0.39) | (0.52) | (0.39) | (0.55) | (0.38) | (0.38) | (0.51) | (0.11) |
| Weighted Average Shares Outstanding (Basic) | 62,666 | 61,967 | 62,024 | 61,902 | 61,792 | 53,751 | 54,629 | 54,452 |
| Weighted Average Shares Outstanding (Diluted) | 62,666 | 61,967 | 62,024 | 61,902 | 61,792 | 53,751 | 54,629 | 54,452 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About JANX
Janux Therapeutics, Inc. (NASDAQ: JANX) is a stock listed on the Nasdaq Stock Market under the ticker symbol JANX. It last traded at $17.55 (Nov 2, 2026, 3:37 PM ET), up 0.5% on the day. That gives Janux Therapeutics a market capitalisation of $1.1B.
Over the past 52 weeks JANX has traded between $12.12 and $35.34.
For the quarter ended Mar 31, 2026 it reported a net loss of $24.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$24.4M |
| Dec 31, 2025 | — | -$31.9M |
| Sep 30, 2025 | — | -$24.3M |
| Jun 30, 2025 | — | -$33.9M |
From Janux Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…